Home > Oncology > SABCS 2021 > Basic and Translational Research > Loss of ASXL1 tumour suppressor promotes resistance to CDK4/6 inhibitors

Loss of ASXL1 tumour suppressor promotes resistance to CDK4/6 inhibitors

Presented By
Dr Dhivya Sudhan, UT Southwestern Medical Center, TX, USA
Conference
SABCS 2021
The pathways leading to CDK4/6 inhibitor resistance are not yet clear. Using a technique called ‘accelerated mutagenesis,’ researchers unravelled the role of ASXL1 loss in CDK4/6 inhibitor resistance. CDK4/6 inhibitors in combination with anti-oestrogens have prolonged survival of patients with oestrogen receptor (ER)-positive/HER2-negative metastatic breast cancer. However, this combination is not curative, mainly due to acquired drug resistance. Knowledge about mechanisms of such resistance remains incomplete. Dr Dhivya Sudhan (UT Southwestern Medical Center, TX, USA) reported results of new insights in the pathways leading to CDK4/6 inhibitor resistance [1]. Using CRISPR/Cas9 to delete the DNA mismatch repair gene MSH2 in MCF7 and T47D ER-positive breast cancer cells, Dr Sudhan and colleagues obtained cells with drug resistance-associated mutations. Clones resistant to CDK4/6 inhibitor...


Please login to read the full text of the article.


If you have no account yet, please register now.





Posted on